Background. We estimated the vaccine effectiveness (VE) of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis among adolescents during a statewide outbreak of pertussis in Wisconsin during 2012.
vaccine (DTaP) [3, 4] has been suggested as a factor contributing to this increased occurrence [5] [6] [7] . Results of recent studies suggest that receipt of priming doses using DTwP is more effective in preventing pertussis than receipt of priming doses using DTaP [8] [9] [10] and that DTaP-induced immunity wanes during the years following dose 5 [11] [12] [13] . Formulation of vaccines that induce long-lasting protection against pertussis has been complicated by an incomplete understanding of the correlates of protection against pertussis [14] .
To reduce the burden and reservoir of pertussis among adolescents, during March 2006 the Advisory Committee on Immunization Practices recommended a 1-time booster dose of a new tetanus-diphtheria-acellular pertussis vaccine (Tdap) for routine use among adolescents aged 11-12 years [15] . Two brands of Tdap, Adacel (Sanofi Pasteur, Toronto, Canada) and Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium), were licensed for use in the United States during 2005. The Tdap brands differ in the number and concentration of B. pertussis antigens and generally contain reduced quantities of these antigens, compared with each company's DTaP formulations. Because of recent introduction, Tdap effectiveness several years after receipt has not been measured in a large populationbased study, and the effectiveness of the Tdap products has not been compared.
During [2003] [2004] [2005] , prior to Tdap availability, a large (7525 reported cases) statewide outbreak of pertussis occurred in Wisconsin, with high incidence rates reported among adolescents. During 2008-2010, a requirement was phased in for all Wisconsin adolescents to receive 1 Tdap dose before entry into grades 6-12 [16] . Despite these measures, another statewide outbreak (6462 reported cases) of pertussis occurred in Wisconsin during 2012 [17] ; 25% of cases occurred among adolescents aged 11-14 years, 76% of whom previously received Tdap. The objective of this study was to investigate the effectiveness of Tdap, by brand and time since receipt, in preventing pertussis during the 2012 outbreak among age cohorts of adolescents who likely never received DTwP.
METHODS

Study Design
We used the population-based Wisconsin Immunization Registry (WIR) to construct 2 analysis cohorts and collect Tdap vaccination histories. Among the full cohort of Wisconsin residents born during 1998-2000, we estimated Tdap vaccine effectiveness (VE), by brand and year of receipt, for preventing pertussis during 2012. Among the subset of the full cohort that received Tdap before 2012 (the Tdap cohort), we examined the incidence of pertussis during 2012, by Tdap brand and year of receipt.
The WIR
The WIR is a statewide, population-based immunization information system (IIS) that records and tracks immunization histories for Wisconsin residents of all ages [18] [19] [20] [21] , the number of organizations transmitting information to the WIR and percentage of DTaP and Tdap doses with TN and LN have increased (Figure 1 ).
Pertussis Case Reporting and Case Definition
Pertussis is a notifiable disease in Wisconsin. We reviewed all reports of pertussis with cough onsets during 2008-2012 among Wisconsin residents born during 1998-2000 that were submitted to WDPH.
We defined a case of pertussis as an acute cough illness with onset during 2012 that met the Council of State and Territorial Epidemiologists (CSTE) definition of confirmed: an illness of any duration in a patient with a clinical specimen culture positive for B. pertussis or an illness meeting the CSTE clinical case definition (CCD) of pertussis (cough ≥14 days duration with whoop, paroxysms, or posttussive vomiting) in a patient with a clinical specimen polymerase chain reaction (PCR) positive for B. pertussis [22] .
We defined a prior incident of pertussis as an acute cough illness with cough onset during 2008-2011 in a patient with symptoms meeting the CCD of pertussis or clinical specimen PCR or culture positive for B. pertussis.
Full Cohort
To construct the full cohort of Wisconsin residents born during 1998-2000, we selected all WIR client records with Wisconsin addresses, birth dates during 1998-2000, and no dates of death and matched them to cases and prior incidents of pertussis by name and birth date (and, if necessary, by address or mother's name; Figure 2) . Often, the addresses of WIR clients who leave Wisconsin are not updated in WIR. Consequently, as more individuals moved into Wisconsin, the numbers of clients in WIR for these age cohorts became substantially larger (by 21%) than corresponding population estimates [23] . We adjusted the full cohort to equal the population estimate for each age cohort using the following method. All WIR clients with a record of Tdap receipt or with a match to a pertussis case were assumed to be Wisconsin residents during 2012 and were included, along with their demographic and immunization histories, in the full cohort. Among WIR clients with no record of Tdap receipt and no match to a pertussis case, we could not specify precisely which were living in Wisconsin but had not received Tdap and which had moved from Wisconsin. Therefore, we included in the full cohort a sample of WIR clients with no record of Tdap receipt and no match to a pertussis case, selected by birth year, so that the sum of all clients in each age cohort was equal to the population estimate. To account for the uncertainty of precisely which clients were included in this sample, for these clients we retained only birth year, Tdap status, and pertussis case status. Demographic information, residence location, and DTaP vaccination history were not retained; consequently, analyses using the full cohort could not be adjusted for these variables.
Tdap Cohort
To further examine the risk of pertussis among a population with demographic, residence location, and DTaP vaccination data available, we constructed the Tdap cohort by selecting WIR clients from the full cohort who received Tdap during 2008-2011 ( Figure 2 ).
Exclusion Criteria
Any clients matched to prior incidents of pertussis were excluded from both cohorts. Cases of pertussis not matched to WIR clients were excluded.
Vaccination Histories
For all clients, history of Tdap receipt was collected from the WIR only and defined as vaccination with Tdap or DTaP on or after the 10th birthday and before cough onset (if a case-client) or before 18 December 2012. Because of delays in developing immunity after Tdap vaccination, all receipt dates were adjusted (14 days were added to the vaccination date). Therefore, among case-clients, doses with vaccination dates <14 days before cough onset were excluded. To limit differential ascertainment of vaccination status, we used WIR as the only source of vaccination information for case-and noncase-clients and, among case-clients, we excluded Tdap doses administered before cough onset but entered into the WIR (per the data entry electronic time stamp) after cough onset.
Tdap brand was obtained from the TN field. During 2008-2012, Boostrix and Adacel had distinctly different LNs (first characters were "A" for Boostrix and "C" or "U" for Adacel); therefore, when LN was available, brand was assigned on the basis of the first character. When TN and LN were both available from WIR, they were compared to detect discordances; when discordancies were detected, brand was assigned on the basis of the LN. DTaP doses received on or after the 10th birthday were categorized as a separate Tdap brand.
Among the Tdap cohort, the number of DTaP doses received before the 10th birthday and date of last DTaP dose were collected from WIR only. 
Statistical Analyses
Data analyses were conducted using SAS, version 9.3 (Cary, NC). Incidence rates of pertussis during 2012 per 100 000 person-years at risk were calculated. Noncase-clients contributed to persontime at risk during all of 2012. Case-clients stopped contributing to person-time at risk on the cough onset date. A total of 376 WIR clients were matched to prior incidents of pertussis and were excluded. Among the WIR clients who had no record of Tdap receipt and were not matched to a case or prior incident of pertussis, 47 914 were excluded to reduce the size of each age cohort to the 2012 population estimate for each age cohort [23] . This was necessary because it could not be determined whether WIR clients who had no record of Tdap receipt and were not matched to a case of pertussis had not received Tdap or were no longer Wisconsin residents. Among the full cohort, we estimated incidence rate ratios (IRRs) of pertussis by Tdap receipt year and brand, using Poisson regression with data for unvaccinated individuals as the reference group. Birth year was evaluated as a potential confounder and tested for collinearity with Tdap receipt year. Separate models were fit for clients with Tdap receipt dates during 2008-2011 and during 2012. In the latter model, Tdap receipt was treated as a time-varying covariate with vaccinated clients contributing to person-time at risk in both the vaccinated and unvaccinated groups to account for change in Tdap receipt status. VE estimates were calculated as [1.0 − IRR] × 100% and reported with corresponding 95% confidence intervals (CIs).
Among the Tdap cohort, we estimated IRRs of pertussis by Tdap brand and year of receipt using Poisson regression. Sex, age on 1 January 2012, Wisconsin region of residence [24] , number of DTaP doses received before the 10th birthday, years since last DTaP dose, and age at Tdap receipt were evaluated as potential confounders, and relationships were evaluated for effect modification. The most parsimonious model excluding collinear covariates was selected.
To examine the impact of missing Tdap brand on our IRR estimates by brand among the full cohort and Tdap cohort, we conducted sensitivity analyses using multiple imputation under the missing-at-random assumption [25] . Missing brand names were imputed (given a value of Adacel or Boostrix) using the logistic regression multiple imputation method, with provider, Tdap receipt date, and age at receipt as predictors of brand. The SAS procedure MI was used to generate 5 imputed data sets (relative efficiency rate, 96%) [26] . IRRs for each imputed data set and corresponding variances and covariances were calculated using Poisson regression. Using the SAS procedure MIANALYZE, the results from the 5 data sets were combined for overall inferences, accounting for variability between imputations.
RESULTS
Figure 2 depicts inclusion of WIR clients into the full cohort (N = 225 130) and Tdap cohort (N = 172 011). Among 959 pertussis cases with onsets during 2012 (all PCR positive, 3 also culture positive) reported to WDPH, 940 (98%) were matched to WIR clients. Specimens from 494 case-clients (53%) were tested using PCR assays that detect both B. pertussis (IS481) and Bordetella parapertussis (IS1001); 1 (0.2%) was positive for both species. No specimens were tested for pertactin expression.
Among Table 2 ). Additionally, unadjusted and birth-yearadjusted point estimates of VE were greater among Boostrix recipients than among Adacel recipients during each year of Tdap receipt (Table 2) .
When clients with imputed brand names were included (Supplementary Table 1 ) and a more inclusive case definition was used (Supplementary Table 2) , the results were similar: point estimates of VE were greater among Boostrix recipients than among Adacel recipients during each year of Tdap receipt.
Tdap Cohort
Characteristics of the Tdap cohort, by brand received, are presented in Table 3 . Adacel recipients were slightly older on 1 January 2012 than Boostrix recipients. Receipt of Adacel and Boostrix varied by region of residence. Receipt of Tdap at age 10 years was more common among Boostrix recipients, consistent with the approved earliest ages of use (Boostrix, 10 years; Adacel, 11 years). Median time from Tdap receipt to 1 January 2012 was 1.2 years among Adacel and Boostrix recipients. Among Adacel and Boostrix recipients, differences in percentages who received ≥4 DTaP doses and times from last DTaP dose were small. Data regarding formulation of DTaP doses received were missing for 78% of all doses and 86% of first doses documented in WIR.
In unadjusted analyses, the incidence of pertussis increased with increasing age, increasing time since Tdap receipt, and increasing time since the last DTaP dose (Table 4) . Pertussis incidence varied significantly by region of residence and age at Tdap receipt and was higher among Adacel recipients than among Boostrix recipients.
After adjustment for region of residence, receipt of Boostrix, compared with Adacel, was associated with a 38% decreased incidence of pertussis (IRR, 0.62 [95% CI, .52-.74]), and compared with receipt during 2011, increasing time since Tdap receipt was associated with an increasing incidence of pertussis ( Table 5 ). The effect of time since receipt did not vary significantly by brand (P = .89). Results were similar in sensitivity analyses when all who received Tdap at age 10 years were excluded and when unspecified Tdap brand names were imputed to have a value of Adacel or Boostrix. [27] [28] [29] . Our observations of decreasing effectiveness with increasing time since Tdap receipt were corroborated with adjusted analyses among the Tdap cohort and are similar to estimates from a case-control study conducted during the 2012 pertussis outbreak in Washington state among adolescents aged 11-14 years; estimated Tdap VE declined from 75% to 41%, respectively, <1 and ≥2 years after vaccination [30] . Together with observations of waning immunity following DTaP receipt [11] [12] [13] , our results provide additional evidence of a limited duration of protection induced by acellular pertussis vaccines and the need for new pertussis vaccines that provide long-lasting protection [6, 31] .
Our results are the first to suggest a difference in Tdap effectiveness by brand, with apparent waning of immunity among recipients of both brands. Among our cohort, Boostrix appeared to be more effective than Adacel in preventing pertussis, and in sensitivity analyses, including adjusted analyses among the Tdap cohort, the trends were similar. It is possible that unknown provider-or patient-related factors associated with the brand of Tdap recorded in WIR and having reported, laboratoryconfirmed pertussis could have contributed to our observed differences in effectiveness by brand; however, it is also biologically plausible that Tdap effectiveness varied by brand because the products differ in composition (Supplementary Table 3) .
Results of epidemiologic [9, 10] and antibody-response studies [32, 33] suggest that the formulations of the priming doses of pertussis vaccine received influence future immunity to pertussis, perhaps by linked epitope suppression [32, 34] . Following pertussis infection or Tdap vaccination, antibody responses to B. pertussis antigens were more robust if the antigens had been received during priming [32, 33] . These findings suggest PT and FHA quantities (micrograms/dose) are greater in Boostrix than Adacel. Both antigens would have been received among the majority of the cohort during priming. Adacel contains fimbriae 2 and 3, whereas Boostrix does not, but fimbriae 3 was not available in DTaP priming formulations, and fimbriae 2 was available in only 1 vaccine. Pertactin quantity is greater in Adacel, but the effectiveness of this antigen may vary by geographic location and time because the prevalence of B. pertussis strains that do not express pertactin, currently unknown in Wisconsin, appears to be increasing in the United States [35] [36] [37] .
Results of a study conducted in Italy demonstrated that immunoglobulin G responses to PT persisted longer following receipt of Boostrix among children primed with Infanrixcontaining vaccine than among children primed with a 2-component (PT and FHA) DTaP-containing vaccine (Hexavac, Sanofi Pasteur), despite Infanrix and Hexavac having the same quantity of PT [33] . These data suggest that protection following Boostrix receipt may persist longer among those primed with Infanrix and that the duration of protection may vary by priming vaccine received, perhaps as a result of differences in vaccine composition or preparation [33] . Studies among adolescents with known DTaP histories are needed to investigate whether the effectiveness of Adacel and Boostrix varies with the DTaP formulation(s) received during childhood. As data included in the WIR and other IISs become more complete through quality improvement initiatives, IISs may be useful in future investigations of this issue. The WIR efficiently provided demographic and immunization information for this study but was limited in identifying unvaccinated clients, previously described as an IIS limitation [38, 39] . Because we could not specify precisely which full cohort clients with no record of Tdap and no case of pertussis resided in Wisconsin during 2012, our VE estimates may be biased or confounded by uncontrolled client-level factors (eg, geographic location).
Using WIR data, our estimate of Tdap uptake among clients becoming 13-14 years old during 2012 was similar to estimates for Wisconsin adolescents from the 2012 National Immunization Survey-Teen ( point estimate [95% CI], 89.8% ± 4.4%) [40] , and the high proportion of corroborating LNs and TNs indicates there was likely not a widespread systematic misrecording of brand information in the WIR. Any misclassification of Tdap receipt or brand would be expected to be nondifferential between case-and noncase-clients because Tdap information was collected from the same source (WIR) for case-and noncase-clients, Tdap information and pertussis case information were collected using separate reporting mechanisms, and, among [28, [41] [42] [43] that can be misclassified as pertussis and result in lower pertussis VE estimates [31, 44] . Because widespread B. parapertussis infections were also reported in Wisconsin during 2012 [41] , we limited our case definition to laboratory-confirmed B. pertussis infection. It is unlikely that coinfection with B. parapertussis or B. holmesii impacted our results: coinfection with B. parapertussis was rare among our cohort, and B. holmesii was not detected among 8505 specimens tested during 2012-2013 at the Wisconsin State Laboratory of Hygiene (David Warshauer, personal communication).
Because we investigated Tdap effectiveness during a large outbreak, our results may not be generalizable to nonoutbreak settings. Additionally, it is possible the statewide pertussis outbreak during 2003-2005 impacted immunity among our cohort, resulting in decreased generalizability to other populations.
In conclusion, our results provide evidence of waning protection from Tdap vaccination among both Adacel and Boostrix recipients. Boostrix was more effective than Adacel in preventing pertussis among our cohort, but these findings may not be generalizable to cohorts of adolescents that received different DTaP vaccines during childhood and should be further examined in studies that include childhood DTaP history. Our study demonstrates the efficiency and limitations of using an IIS to examine vaccine effectiveness. Our results reinforce the needs for enhanced understanding of the correlates of protection against pertussis and for pertussis vaccines that induce durable, highly effective immunity.
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